Cancer Health Forums

Brain Cancer Forums => Living with Brain Cancer => Topic started by: Cancer Health Editors on December 04, 2019, 08:23:17 am

Title: New Treatment Yields Promising Outcomes in High-Risk Neuroblastoma
Post by: Cancer Health Editors on December 04, 2019, 08:23:17 am
Combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy yielded promising two-year event-free survival in pediatric patients with newly diagnosed high-risk neuroblastoma, according to results from a phase II trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Approximately 650 children are diagnosed with neuroblastoma each year in North America, and the disease predominantly affects children under the age of five years. Because the symptoms can be non-specific, about half of patients are diagnosed after the cancer has spread and progressed to high-risk neuroblastoma, according to Wayne L. Furman, MD, member of the Department of Oncology at St. Jude Children’s Research Hospital.

Patients with high-risk neuroblastoma undergo intense treatment that includes chemotherapy, surgery, stem cell transplant, radiotherapy, a biologic agent, and treatment with a monoclonal anti-GD2 antibody called dinutuximab. “Despite the aggressive treatment these kids receive, more than half have disease recurrence,” said Furman.